Market capitalization | $69.90m |
Enterprise Value | $70.31m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.56 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-24.43m |
Free Cash Flow (TTM) Free Cash Flow | $-19.46m |
Cash position | $19.65m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Second Sight Medical Products, Inc. forecast:
3 Analysts have issued a Second Sight Medical Products, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.41 -0.41 |
11%
11%
|
|
EBITDA | -24 -24 |
15%
15%
|
EBIT (Operating Income) EBIT | -24 -24 |
14%
14%
|
Net Profit | -23 -23 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
Head office | United States |
CEO | Adam Mendelsohn |
Employees | 44 |
Founded | 2003 |
Website | www.vivani.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.